[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2001121185A - High purity ethyl EPA and other derivatives of EPA for psychiatric and neurological disorders - Google Patents

High purity ethyl EPA and other derivatives of EPA for psychiatric and neurological disorders

Info

Publication number
RU2001121185A
RU2001121185A RU2001121185/14A RU2001121185A RU2001121185A RU 2001121185 A RU2001121185 A RU 2001121185A RU 2001121185/14 A RU2001121185/14 A RU 2001121185/14A RU 2001121185 A RU2001121185 A RU 2001121185A RU 2001121185 A RU2001121185 A RU 2001121185A
Authority
RU
Russia
Prior art keywords
disorder
epa
treatment
pharmaceutical preparation
drug
Prior art date
Application number
RU2001121185/14A
Other languages
Russian (ru)
Other versions
RU2260423C2 (en
Inventor
Малком ПИТ
Кришнарейо Сайтэмрейо ВЭДДЭДИ
Original Assignee
Лэксдейл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9901809.5A external-priority patent/GB9901809D0/en
Application filed by Лэксдейл Лимитед filed Critical Лэксдейл Лимитед
Publication of RU2001121185A publication Critical patent/RU2001121185A/en
Application granted granted Critical
Publication of RU2260423C2 publication Critical patent/RU2260423C2/en

Links

Claims (43)

1. Фармацевтический препарат для лечения или предупреждения психиатрического расстройства или расстройства центральной нервной системы, содержащий эйкозапентаеновую кислоту (ЭПК) в подходящим образом ассимилируемой форме, в котором из всех жирных кислот, присутствующих в этом препарате, по меньшей мере 90% и предпочтительно по меньшей мере 95% находятся в форме ЭПК, и в котором менее 5% и предпочтительно менее 3% находятся в форме докозагексаеновой кислоты (ДГК).1. A pharmaceutical preparation for treating or preventing a psychiatric disorder or a central nervous system disorder containing eicosapentaenoic acid (EPA) in a suitably assimilable form, in which of all the fatty acids present in this preparation is at least 90% and preferably at least at least 95% are in the form of EPA, and in which less than 5% and preferably less than 3% are in the form of docosahexaenoic acid (DHA). 2. Фармацевтический препарат по п.1, в котором ЭПК находится в форме этил-ЭПК, литий-ЭПК, моно-, ди- или триглицерида ЭПК, либо любых других эфира или соли ЭПК, либо в форме свободной кислоты ЭПК или другого подходящего биодоступного производного, которое повышает уровни ЭПК в организме.2. The pharmaceutical preparation according to claim 1, in which the EPA is in the form of ethyl EPA, lithium EPA, mono-, di- or triglyceride EPA, or any other ester or salt of EPA, or in the form of a free acid EPA or other suitable bioavailable a derivative that increases EPA levels in the body. 3. Фармацевтический препарат по п.1 или 2, в котором ЭПК находится в форме 2-замещенного производного или другого производного, которое снижает скорость окисления, не уменьшая ее биологической активности.3. The pharmaceutical preparation according to claim 1 or 2, in which the EPA is in the form of a 2-substituted derivative or other derivative, which reduces the rate of oxidation without decreasing its biological activity. 4. Фармацевтический препарат по любому из пп.1-3, где расстройство представляет собой шизофрению, шизоаффективное расстройство или шизотипичное расстройство.4. The pharmaceutical preparation according to any one of claims 1 to 3, where the disorder is schizophrenia, schizoaffective disorder or schizotypal disorder. 5. Фармацевтический препарат по любому из пп.1-3, где расстройство представляет собой депрессию или манию-депрессию (биполярное расстройство).5. The pharmaceutical preparation according to any one of claims 1 to 3, wherein the disorder is depression or mania depression (bipolar disorder). 6. Фармацевтический препарат по любому из пп.1-3, где расстройство представляет собой тревожное или паническое расстройство, либо социальную фобию, либо расстройство сна, либо дефицит внимания, кондуктивное расстройство, гиперактивное или личностное расстройство.6. The pharmaceutical preparation according to any one of claims 1 to 3, where the disorder is an anxiety or panic disorder, or social phobia, or sleep disorder, or attention deficit disorder, conductive disorder, hyperactive or personality disorder. 7. Фармацевтический препарат по любому из пп.1-3, где расстройство представляет собой болезнь Альцгеймера или другую деменцию, включая мультиинфарктную деменцию, болезнь телец Леви и заболевания, присущие прионным расстройствам.7. The pharmaceutical preparation according to any one of claims 1 to 3, wherein the disorder is Alzheimer's disease or other dementia, including multi-infarct dementia, Levi's calf disease and diseases inherent in prion disorders. 8. Фармацевтический препарат по любому из пп.1-3, где расстройство представляет собой болезнь Паркинсона или другое расстройство двигательной системы.8. The pharmaceutical preparation according to any one of claims 1 to 3, where the disorder is Parkinson's disease or another disorder of the motor system. 9. Фармацевтический препарат по любому из пп.1-3, где расстройство представляет собой рассеянный склероз.9. The pharmaceutical preparation according to any one of claims 1 to 3, where the disorder is multiple sclerosis. 10. Фармацевтический препарат по любому из пп.1-3, где расстройство представляет собой удар или постударный синдром, либо травму головы или синдром после травмы головы.10. The pharmaceutical preparation according to any one of claims 1 to 3, where the disorder is a stroke or a shock syndrome, or a head injury or a syndrome after a head injury. 11. Фармацевтический препарат по любому из пп.1-3, где расстройство представляет собой эпилепсию.11. The pharmaceutical preparation according to any one of claims 1 to 3, where the disorder is epilepsy. 12. Фармацевтический препарат по любому из пп.1-3, где расстройство представляет собой болезнь Хантингтона или любое другое нейродегенеративное расстройство, в частности любое расстройство вследствие повторов тринуклеотидов, включая атаксию Фридрайха, миотоническую дистрофию и синдром ломкой Х хромосомы.12. The pharmaceutical preparation according to any one of claims 1 to 3, wherein the disorder is Huntington’s disease or any other neurodegenerative disorder, in particular any disorder due to repeats of trinucleotides, including Friedreich ataxia, myotonic dystrophy, and fragile X chromosome syndrome. 13. Фармацевтический препарат по любому из пп.1-3, но для лечения воспалительных расстройств суставов, дыхательной системы, желудочно-кишечной системы, почек, кожи, репродуктивной системы и всех других органов.13. The pharmaceutical preparation according to any one of claims 1 to 3, but for the treatment of inflammatory disorders of the joints, respiratory system, gastrointestinal system, kidneys, skin, reproductive system and all other organs. 14. Препараты для применения при психиатрических и неврологических расстройствах, в которых лекарственное средство, которое воздействует в основном на метаболизм или рецепторы нейротрансмиттеров, приготовлено для совместного введения с фармацевтическим препаратом по любому из пп.1-3.14. Preparations for use in psychiatric and neurological disorders, in which a drug that mainly affects the metabolism or receptors of neurotransmitters is prepared for co-administration with a pharmaceutical preparation according to any one of claims 1 to 3. 15. Фармацевтический препарат, содержащий препарат по любому из пп.1-3 вместе с лекарственным средством, которое воздействует в основном на метаболизм или рецепторы нейротрансмиттеров.15. A pharmaceutical preparation containing the drug according to any one of claims 1 to 3, together with a drug that mainly affects the metabolism or receptors of neurotransmitters. 16. Препарат по п.14 или 15, в котором лекарственное средство представляет собой клозапин.16. The drug according to 14 or 15, in which the drug is clozapine. 17. Препарат по п.14 или 15, в котором лекарственное средство представляет собой любое лекарственное средство из класса типичных или атипичных нейролептиков, включая хлорпромазин, галоперидол, рисперидон, оланзапин, сертиндол, зипразидон, зотепин или амисульпирид.17. The drug according to 14 or 15, in which the drug is any drug from the class of typical or atypical antipsychotics, including chlorpromazine, haloperidol, risperidone, olanzapine, sertindole, ziprasidone, zotepine or amisulpiride. 18. Способ лечения или предупреждения психиатрического расстройства или расстройства центральной нервной системы, при котором осуществляют стадию введения композиции по пп.1-3.18. A method of treating or preventing a psychiatric disorder or disorder of the central nervous system, in which the stage of administration of the composition according to claims 1-3 is carried out. 19. Способ лечения психиатрических и неврологических расстройств, при котором лекарственное средство, которое воздействует в основном на метаболизм или рецепторы нейротрансмиттеров, используют совместно с фармацевтическим препаратом по любому из пп.1-3.19. A method of treating psychiatric and neurological disorders, in which a drug that mainly affects the metabolism or receptors of neurotransmitters is used in conjunction with a pharmaceutical preparation according to any one of claims 1 to 3. 20. Способ лечения по п.18 или 19, при котором расстройство, которое лечат, представляет собой шизофрению, шизоаффективное расстройство или шизотипичное расстройство.20. The method of treatment according to claim 18 or 19, wherein the disorder that is being treated is schizophrenia, schizoaffective disorder or schizotypal disorder. 21. Способ лечения по п.18 или 19, при котором расстройство, которое лечат, представляет собой депрессию или биполярное расстройство.21. The method of treatment according to claim 18 or 19, wherein the disorder that is being treated is depression or bipolar disorder. 22. Способ лечения по п.18 или 19, при котором расстройство, которое лечат, представляет собой расстройства сна, тревожные расстройства, панические расстройства, социальные фобии, кондуктивные расстройства, личностные расстройства и расстройства внимания и гиперактивные расстройства.22. The method of treatment according to claim 18 or 19, wherein the disorder to be treated is sleep disorder, anxiety disorder, panic disorder, social phobia, conductive disorder, personality disorder and attention disorder, and hyperactive disorder. 23. Способ лечения по п.18 или 19, при котором расстройство, которое лечат, представляет собой любую форму деменции, включая болезнь Альцгеймера, болезнь телец Леви, сосудистую деменцию и другие деменции.23. The method of treatment according to claim 18 or 19, wherein the disorder that is treated is any form of dementia, including Alzheimer's disease, Levi's calf disease, vascular dementia, and other dementia. 24. Способ лечения по п.18 или 19, при котором расстройство, которое лечат, представляет собой любую форму неврологического заболевания, включая болезнь Паркинсона, болезнь Хантингтона, рассеянный склероз, удар и эпилепсию.24. The treatment method of claim 18 or 19, wherein the disorder that is treated is any form of neurological disease, including Parkinson's disease, Huntington's disease, multiple sclerosis, stroke and epilepsy. 25. Способ лечения или предупреждения побочных действий лекарственного средства, используемого при лечении психиатрических или неврологических расстройств, при котором вводят это лекарственное средство и фармацевтический препарат по любому из пп.1-3.25. A method of treating or preventing side effects of a drug used in the treatment of psychiatric or neurological disorders, in which this drug and the pharmaceutical preparation according to any one of claims 1 to 3 are administered. 26. Способ лечения воспалительных расстройств суставов, дыхательной системы, желудочно-кишечной системы, почек, кожи, репродуктивной системы и всех других органов, при котором вводят фармацевтическую композицию по п.13.26. A method of treating inflammatory disorders of the joints, respiratory system, gastrointestinal system, kidneys, skin, reproductive system and all other organs, in which the pharmaceutical composition according to item 13 is administered. 27. Применение препарата, содержащего ЭПК в подходящим образом ассимилируемой форме, в котором из всех жирных кислот, присутствующих в этом препарате, по меньшей мере 90% и предпочтительно по меньшей мере 95% находятся в форме ЭПК, и в котором менее 5% и предпочтительно менее 3% находятся в форме докозагексаеновой кислоты (ДГК), в изготовлении лекарства для лечения или предупреждения психиатрического расстройства или расстройства центральной нервной системы.27. The use of a preparation containing EPA in a suitably assimilable form, in which of all the fatty acids present in this preparation, at least 90% and preferably at least 95% are in the form of EPA, and in which less than 5% and preferably less than 3% are in the form of docosahexaenoic acid (DHA), in the manufacture of a medicament for the treatment or prevention of a psychiatric disorder or a central nervous system disorder. 28. Применение по п.27, где ЭПК находится в форме этил-ЭПК, литий-ЭПК, моно-, ди- или триглицерида ЭПК, либо любых других эфира или соли ЭПК, либо в форме свободной кислоты ЭПК или другого подходящего биодоступного производного, которое повышает уровни ЭПК в организме.28. The application of clause 27, where the EPA is in the form of ethyl EPA, lithium EPA, mono-, di- or triglyceride EPA, or any other ester or salt of EPA, or in the form of a free acid EPA or other suitable bioavailable derivative, which increases EPA levels in the body. 29. Применение по п.27 или 28, где ЭПК находится в форме 2-замещенного производного или другого производного, которое снижает скорость окисления, не уменьшая ее биологической активности.29. The use of claim 27 or 28, wherein the EPA is in the form of a 2-substituted derivative or other derivative that reduces the oxidation rate without decreasing its biological activity. 30. Применение по любому из пп.27-29 для изготовления лекарства для лечения шизофрении, шизоаффективного расстройства или шизотипичного расстройства.30. The use according to any one of paragraphs.27-29 for the manufacture of a medicament for the treatment of schizophrenia, schizoaffective disorder or schizotypal disorder. 31. Применение по любому из пп.27-29 для изготовления лекарства для лечения депрессии или мании-депрессии (биполярного расстройства).31. The use according to any one of paragraphs.27-29 for the manufacture of a medicament for the treatment of depression or mania-depression (bipolar disorder). 32. Применение по любому из пп.27-29 для изготовления лекарства для лечения тревожного или панического расстройства, либо социальной фобии, либо расстройства сна, либо дефицита внимания, кондуктивного расстройства, гиперактивного или личностного расстройства.32. The use according to any one of claims 27 to 29 for the manufacture of a medicament for the treatment of anxiety or panic disorder, or social phobia, or sleep disorder, or attention deficit, conductive disorder, hyperactive or personality disorder. 33. Применение по любому из пп.27-29 для изготовления лекарства для лечения болезни Альцгеймера или другой деменции, включая мультиинфарктную деменцию, болезнь телец Леви и заболевания, присущие прионным расстройствам.33. The use according to any one of paragraphs.27-29 for the manufacture of a medicament for the treatment of Alzheimer's disease or other dementia, including multi-infarct dementia, Lewy body disease and diseases inherent in prion disorders. 34. Применение по любому из пп.27-29 для изготовления лекарства для лечения болезни Паркинсона или другого расстройства двигательной системы.34. The use according to any one of paragraphs.27-29 for the manufacture of a medicament for the treatment of Parkinson's disease or other disorders of the motor system. 35. Применение по любому из пп.27-29 для изготовления лекарства для лечения рассеянного склероза.35. The use according to any one of paragraphs.27-29 for the manufacture of a medicament for the treatment of multiple sclerosis. 36. Применение по любому из пп.27-29 для изготовления лекарства для лечения удара или постударного синдрома, либо травмы головы или синдрома после травмы головы.36. The use according to any one of paragraphs.27-29 for the manufacture of a medicament for the treatment of stroke or shock syndrome, or head injury or syndrome after head injury. 37. Применение по любому из пп.27-29 для изготовления лекарства для лечения эпилепсии.37. The use according to any one of paragraphs.27-29 for the manufacture of a medicament for the treatment of epilepsy. 38. Применение по любому из пп.27-29 для изготовления лекарства для лечения болезни Хантингтона или любого другого нейродегенеративного расстройства, в частности любого расстройства вследствие повторов тринуклеотидов, включая атаксию Фридрайха, миотоническую дистрофию и синдром ломкой Х хромосомы.38. The use according to any one of claims 27-29 for the manufacture of a medicament for the treatment of Huntington's disease or any other neurodegenerative disorder, in particular any disorder due to repeats of trinucleotides, including Friedreich ataxia, myotonic dystrophy, and fragile X chromosome syndrome. 39. Применение по любому из пп.27-38, где препарат дополнительно содержит лекарственное средство, которое воздействует в основном на метаболизм или рецепторы нейротрансмиттеров.39. The use according to any one of paragraphs.27-38, where the drug further comprises a drug that mainly affects the metabolism or receptors of neurotransmitters. 40. Применение по п.39, где лекарственное средство представляет собой клозапин.40. The use of claim 39, wherein the drug is clozapine. 41. Применение по п.39, где лекарственное средство представляет собой любое лекарственное средство из класса типичных или атипичных нейролептиков, включая хлорпромазин, галоперидол, рисперидон, оланзапин, сертиндол, зипразидон, зотепин или амисульпирид.41. The use of claim 39, wherein the drug is any drug from the class of typical or atypical antipsychotics, including chlorpromazine, haloperidol, risperidone, olanzapine, sertindole, ziprasidone, zotepine or amisulpiride. 42. Применение по любому из пп.27-29, но для изготовления лекарства для лечения воспалительных расстройств суставов, дыхательной системы, желудочно-кишечной системы, почек, кожи, репродуктивной системы и всех других органов.42. The use according to any one of paragraphs.27-29, but for the manufacture of a medicament for the treatment of inflammatory disorders of the joints, respiratory system, gastrointestinal system, kidneys, skin, reproductive system and all other organs. 43. Фармацевтический препарат для лечения или предупреждения психиатрического расстройства или расстройства центральной нервной системы, содержащий ЭПК в подходящим образом ассимилируемой форме, в котором из всех жирных кислот, присутствующих в этом препарате, по меньшей мере 90% и предпочтительно по меньшей мере 95% находятся в форме ЭПК, и в котором докозагексаеновая кислота (ДГК) по существу отсутствует.43. A pharmaceutical preparation for treating or preventing a psychiatric disorder or a central nervous system disorder containing EPA in a suitably assimilable form, in which of all the fatty acids present in this preparation, at least 90% and preferably at least 95% are in form of EPA, and in which docosahexaenoic acid (DHA) is essentially absent.
RU2001121185/14A 1999-01-27 2000-01-21 Ethyleicosapentaenoic acid of high purity degree and other derivatives of eicosapentaenoic acid for psychiatric and neurological disorders RU2260423C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9901809.5 1999-01-27
GBGB9901809.5A GB9901809D0 (en) 1999-01-27 1999-01-27 Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

Publications (2)

Publication Number Publication Date
RU2001121185A true RU2001121185A (en) 2003-05-20
RU2260423C2 RU2260423C2 (en) 2005-09-20

Family

ID=10846603

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001121185/14A RU2260423C2 (en) 1999-01-27 2000-01-21 Ethyleicosapentaenoic acid of high purity degree and other derivatives of eicosapentaenoic acid for psychiatric and neurological disorders

Country Status (34)

Country Link
US (10) US6384077B1 (en)
EP (2) EP1417963A1 (en)
JP (1) JP4959055B2 (en)
KR (1) KR100760038B1 (en)
CN (2) CN100423718C (en)
AT (1) ATE300296T1 (en)
AU (1) AU3065700A (en)
BR (1) BR0007743A (en)
CA (1) CA2360776C (en)
CZ (1) CZ20012695A3 (en)
DE (1) DE60021525T2 (en)
DK (1) DK1148873T3 (en)
EE (1) EE04629B1 (en)
ES (1) ES2246825T3 (en)
GB (1) GB9901809D0 (en)
HK (1) HK1039564B (en)
HR (1) HRP20010558A2 (en)
HU (1) HU226713B1 (en)
IL (2) IL144502A0 (en)
IS (1) IS5988A (en)
MX (1) MXPA01007662A (en)
MY (1) MY136927A (en)
NO (1) NO20013546L (en)
NZ (1) NZ513172A (en)
PL (1) PL199778B1 (en)
PT (1) PT1148873E (en)
RS (1) RS50133B (en)
RU (1) RU2260423C2 (en)
SK (1) SK10392001A3 (en)
TR (2) TR200102170T2 (en)
TW (1) TWI228041B (en)
UA (1) UA76405C2 (en)
WO (1) WO2000044361A2 (en)
ZA (1) ZA200106105B (en)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
WO2000074784A1 (en) * 1999-06-09 2000-12-14 Eli Lilly And Company Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
US6737078B1 (en) * 1999-11-24 2004-05-18 The Iams Company Process for enhancing canine and feline reproductive performance
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US20050032897A1 (en) * 2000-11-22 2005-02-10 The Iams Company Process for enhancing canine and feline reproductive performance
NL1019368C2 (en) * 2001-11-14 2003-05-20 Nutricia Nv Preparation for improving receptor performance.
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
BR0309740A (en) * 2002-05-03 2005-02-22 Pronova Biocare As Use of eicosapentaenoic acid (epa), docosaexaenoic acid (dha) or a mixture of epa and dha or a pharmaceutically acceptable salt or derivative thereof
EP2295529B2 (en) * 2002-07-11 2022-05-18 Basf As Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
SE0202188D0 (en) * 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
US7410663B2 (en) * 2002-08-07 2008-08-12 Kao Corporation Oil or fat composition
GB0221480D0 (en) * 2002-09-16 2002-10-23 Laxdale Ltd Treatment of anorexia nervosa (AN) and bulimia
GB0228079D0 (en) * 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease
GB0301701D0 (en) * 2003-01-24 2003-02-26 Ensay Ltd Psoriasis and Eicosapentaenoic acid
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
EP2324828A1 (en) * 2003-08-18 2011-05-25 BTG International Limited Treatment for neurodegenerative conditions
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
FR2860976B1 (en) * 2003-10-20 2006-02-10 Ravi Shrivastava NOVEL SYNERGISTIC COMPOSITIONS FOR IMPROVING THE BIODAVAILABILITY AND EFFICIENCY OF POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF BRAIN FUNCTIONING DISORDERS.
EP1683519A4 (en) * 2003-11-14 2009-04-01 Mochida Pharm Co Ltd Preventive/therapeutic agent for speech disorder
US6936598B2 (en) * 2003-11-21 2005-08-30 Hill's Pet Nutrition, Inc. Composition and method
US7754677B2 (en) * 2003-12-05 2010-07-13 Hill's Pet Nutrition, Inc. Composition and method for reducing diarrhea in a mammal
GB2409644B (en) * 2003-12-31 2005-12-21 Igennus Ltd Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
ITMI20040069A1 (en) * 2004-01-21 2004-04-21 Tiberio Bruzzese USE OF HIGH CONCENTRATION N-3 FATTY ACID COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
PT1773878E (en) 2004-07-19 2015-06-05 Biocon Ltd Insulin-oligomer conjugates, formulations and uses thereof
ES2574557T3 (en) * 2004-09-21 2016-06-20 Btg International Limited Dopamine Mimetics
US20100021555A1 (en) * 2004-10-15 2010-01-28 Karl Geiringer Compositions containing high omega-3 and low saturated fatty acid levels
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
US20090054523A1 (en) * 2005-01-24 2009-02-26 Morten Bryhn Use of a Fatty Acid Composition Containing DHA for the Production of a Medical Product or a Food Stuff for the Treatment of Amyloidos-Related Diseases
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
CN101213281B (en) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 New dha derivatives and their use as medicaments
BRPI0611159A2 (en) * 2005-05-04 2012-07-31 Pronova Biopharma Norge As compost and respective process and manufacture, pharmaceutical and fatty acid compositions, uses of compost and methods of controlling body weight reduction and / or preventing body weight gain, treating and / or preventing obesity or an overweight condition , diabetes, amyloidosis-related diseases, treatment or prophylaxis of multiple risk factors for cardiovascular diseases and prevention of stroke, cerebral ischemic attacks or passengers related to atherosclerosis of various arteries
KR101870626B1 (en) * 2005-07-08 2018-06-26 디에스엠 아이피 어셋츠 비.브이. Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
TWI412361B (en) 2005-07-08 2013-10-21 Mochida Pharm Co Ltd Composition for preventing onset of cardiovascular events
ITMI20051560A1 (en) * 2005-08-10 2007-02-11 Tiberio Bruzzese COMPOSITION OF N-3 FATTY ACIDS WITH HIGH CONCENTRATION OF EPA AND E-O DHA AND CONTAINING N-6 FATTY ACIDS
ES2277557B1 (en) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. USE OF DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF OXIDATIVE CELL DAMAGE.
BRPI0621131A2 (en) 2005-12-21 2011-11-29 Brudy Technology S L use of dha, epa or dha-derived epa to treat a condition associated with cellular oxidative damage
ES2790590T3 (en) * 2006-07-14 2020-10-28 Kaydence Pharma As Pharmaceutical and nutritional products containing vitamin K2
CN101631757A (en) * 2006-11-01 2010-01-20 普罗诺瓦生物医药挪威公司 Omega-3 lipid compounds
RU2507193C2 (en) * 2006-11-01 2014-02-20 Пронова Биофарма Норге А/С Alpha-substituted omega-3 lipids, activators or modulators of peroxisome proliferator activated receptor (ppar)
JP2010508262A (en) * 2006-11-01 2010-03-18 プロノヴァ バイオファーマ ノルゲ アーエス Composition
KR101438177B1 (en) * 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 Alpha-sustituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor(PPAR)
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US20090088400A1 (en) 2007-09-11 2009-04-02 Puymirat Jack Prostaglandin e2 modulation and uses thereof
ES2664822T3 (en) 2007-10-16 2018-04-23 Biocon Limited A solid pharmaceutical composition orally administrable and a process thereof
JP5575651B2 (en) * 2007-10-31 2014-08-20 プロノヴァ バイオファーマ ノルゲ アーエス Novel DHA derivatives and their use as pharmaceuticals
US20090182049A1 (en) * 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
PT2334295T (en) 2008-09-02 2017-09-15 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
WO2010027266A1 (en) * 2008-09-05 2010-03-11 Van De Langenberg, Hendrikus Theodorus Ardina Hubertus Means and methods for counteracting neurological disorders
AU2008361645A1 (en) 2008-09-09 2010-03-18 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
PT2395991E (en) 2009-02-10 2013-09-03 Amarin Pharmaceuticals Ie Ltd Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
ES2881885T3 (en) 2009-03-09 2021-11-30 Basf As Compositions comprising a fatty acid oil blend comprising EPA and DHA in the form of the free acid and a surfactant, and methods and uses thereof
GB0904300D0 (en) 2009-03-12 2009-04-22 Amarin Neuroscience Ltd Essential fatty acid compounds
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
HUE034941T2 (en) 2009-04-29 2018-03-28 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition and methods of using same
AU2014203034B2 (en) * 2009-04-29 2016-09-15 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
KR101958515B1 (en) 2009-06-15 2019-03-14 아마린 파마, 인크. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
EP2480248B1 (en) 2009-09-23 2015-09-02 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
JP2011136948A (en) * 2009-12-28 2011-07-14 Nisshin Oillio Group Ltd Oil-and-fat composition for prevention or treatment of depression or depressed state
WO2011087981A2 (en) * 2010-01-15 2011-07-21 E. I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
AU2011222544A1 (en) * 2010-03-04 2012-09-27 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
GB201020133D0 (en) 2010-11-26 2011-01-12 Royal Holloway & Bedford New College Therapeutic use of compounds
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) * 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
BR112013020346A2 (en) * 2011-02-11 2019-09-24 Du Pont eicosapentaenoic acid concentrate, pharmaceutical product, method of making an eicosapentaenoic acid concentrate and use of microbial oil
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Methods of treating hypertriglyceridemia
WO2013103958A1 (en) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
AU2013235266B2 (en) 2012-03-20 2017-10-19 Particle Dynamics International, Llc Gelling agent-based dosage form
CA3067008C (en) 2012-06-29 2021-10-26 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CA2878267A1 (en) * 2012-06-29 2014-01-03 Amarin Pharmaceuticals Ireland Limited Methods of treating pediatric metabolic syndrome
CA2925804A1 (en) 2012-09-26 2014-04-03 Seth D. Feuerstein Combination methods and compositions including sleep therapeutics for treating mood
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
AU2013354979A1 (en) * 2012-12-06 2015-06-11 Matinas Biopharma, Inc. Administering compositions comprising docosapentaenoic acid
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
WO2014134053A1 (en) * 2013-02-26 2014-09-04 Jiva Pharma, Inc. Ascorbate esters of omega-3 fatty acids
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015085192A1 (en) * 2013-12-05 2015-06-11 Enzymotec Ltd. Serine glycerophospholipid preparation and method for treatment of seizures
EP3118186B1 (en) * 2013-12-11 2022-02-09 Novasep Process Chromatographic facility for producing polyunsaturated fatty acids
US10975031B2 (en) 2014-01-07 2021-04-13 Novasep Process Method for purifying aromatic amino acids
US9540307B2 (en) 2014-05-08 2017-01-10 Jiva Pharma, Inc. Statins of omega-3 polyunsaturated acids for treating hypercholesterolemia
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
RU2582962C1 (en) * 2014-12-23 2016-04-27 Ольга Алексеевна Громова Agent for preventing and treating neurodegenerative pathology and vascular dementia (versions)
US10183044B2 (en) 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11065288B2 (en) * 2017-09-29 2021-07-20 Kinjirushi Co., Ltd. Neuron activator
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2019241563A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering triglyceride levels with a concentrated fish oil-based pharmaceutical composition
CN108721269A (en) * 2018-07-10 2018-11-02 广东海洋大学 A kind of application of EPA with DHA intermixtures in terms of prevention anxiety and anhedonia
HUE067138T2 (en) 2018-09-24 2024-10-28 Amarin Pharmaceuticals Ireland Ltd Methods of reducing the risk of cardiovascular events in a subject
US20230097753A1 (en) * 2020-01-29 2023-03-30 Universitat De Les Illes Balears Alpha-hydroxylated fatty-acid metabolites, medical uses and use as biomarkers
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1021147A (en) * 1972-10-30 1977-11-22 Stephen S. Trond Method for preparing oxysulfide phosphors with large particle size
US4377526A (en) 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
US4526902A (en) 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
US4727340A (en) * 1986-04-30 1988-02-23 Tektronix, Inc. Comb generators
US4920098A (en) * 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5252333A (en) 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
DE3719097C1 (en) * 1987-06-06 1988-06-09 Fratzer Uwe Medicament containing eicosapentaenoic acid and docosahexaenoic acid as unsaturated fatty acids as well as vitamin E.
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
CA1338683C (en) 1988-09-13 1996-10-29 Efamol Holdings Plc Fatty acid therapy and compositions
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
JP2839276B2 (en) 1989-01-23 1998-12-16 日本分光工業株式会社 Supercritical fluid extraction / separation method and apparatus
GB8906369D0 (en) * 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
US5457130A (en) 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
JPH0358926A (en) * 1989-07-27 1991-03-14 Taiyo Fishery Co Ltd Cerebral function-improving composition, learning ability-improving agent, mneme-improving agent, dementia-preventing agent, dementia remedy and functional food having cerebral function-improving activity
CA2043615C (en) * 1990-06-04 2001-08-14 Kazuhiko Hata Method of producing eicosapentaenoic acid or the ester derivative thereof
GB9012651D0 (en) 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
JP3103588B2 (en) * 1990-11-16 2000-10-30 持田製薬株式会社 Lipoprotein (a) lowering agent
SE9101642D0 (en) 1991-05-30 1991-05-30 Kabi Pharmacia Ab phospholipids
US5215630A (en) 1991-06-04 1993-06-01 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
DE4133694C2 (en) * 1991-10-11 1993-10-07 Fresenius Ag Use of an emulsion with polyunsaturated fatty acids for i.v. administration for the treatment of skin diseases
JP3400466B2 (en) * 1991-10-28 2003-04-28 日本水産株式会社 Method for producing high-purity eicosapentaenoic acid or ester thereof
JPH0649479A (en) * 1992-07-28 1994-02-22 Maruha Corp Stabilization of omega,3-unsaturated fatty acid compound
US5516801A (en) * 1992-08-21 1996-05-14 Scotia Holdings Plc Fatty acid treatment for ectopic calcium deposition
US5888541A (en) 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
WO1994028891A1 (en) 1993-06-04 1994-12-22 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5760081A (en) 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
AU711482B2 (en) 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
IT1274734B (en) * 1994-08-25 1997-07-24 Prospa Bv PHARMACEUTICAL COMPOSITIONS CONTAINING POLYUNSATURATED FATTY ACIDS, THEIR ESTERS OR SALTS, WITH VITAMINS OR ANTIOXIDANT PROVITAMINS
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
JP3552810B2 (en) 1995-09-27 2004-08-11 松下電器産業株式会社 Method and device for batch replacement of parts in the parts supply section
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
AU2738497A (en) * 1996-04-24 1997-11-12 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
ID21473A (en) 1996-10-11 1999-06-17 Scotia Holdings Plc PHARMACEUTICAL PRICES CONTAINING EICOSAPENTANOIC ACID AND STEARIDONIC ACID
EP1025842B1 (en) 1997-10-30 2004-07-21 Morishita Jintan Co., Ltd. Double-leyered capsule of unsaturated fatty acid or derivative thereof and process for producing the same
DE69842121D1 (en) * 1997-12-10 2011-03-17 Cyclosporine Therapeutics Ltd OMEGA-3 FATTY ACID PHARMACEUTICAL COMPOSITIONS
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) * 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
PT1072198E (en) * 1999-07-28 2008-06-17 Swiss Caps Rechte & Lizenzen Preparation for use as medicament and/or nutritional supplement
WO2001015552A1 (en) 1999-08-30 2001-03-08 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
ATE305810T1 (en) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con PHARMACEUTICAL COMPOSITION CONTAINING FATTY ACID WHICH IS AT LEAST 80 Wt. CONTAINS EPA AND DHA
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
ITMI20010129A1 (en) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
CN1268328C (en) 2001-05-30 2006-08-09 拉克斯戴尔有限公司 Coenzyme q and eicosapentaenoic acid (EPA)
ITMI20012384A1 (en) 2001-11-12 2003-05-12 Quatex Nv USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF MAJOR CARDIOVASCULAR EVENTS
ITMI20020269A1 (en) 2002-02-12 2003-08-12 Victorix Assets Ltd USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY
US20030166614A1 (en) * 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
US20070087137A9 (en) * 2003-06-26 2007-04-19 Elwakil Hamdy A Decorative laminated safety glass
JP4398862B2 (en) * 2002-08-20 2010-01-13 興和株式会社 Soft capsule
KR100539027B1 (en) 2002-10-18 2005-12-26 현대모비스 주식회사 detection apparatus for steering angle in vehicle
AU2003284633B2 (en) * 2002-11-22 2008-07-10 Nippon Suisan Kaisha, Ltd. External composition containing polyunsaturated fatty acid or its salt or ester
JP2006519244A (en) 2003-03-05 2006-08-24 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング Use of omega-3-fatty acids in the treatment of diabetic patients
GB2409644B (en) * 2003-12-31 2005-12-21 Igennus Ltd Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
EP1830830A4 (en) * 2004-12-06 2010-02-10 Reliant Pharmaceuticals Inc Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20070191467A1 (en) * 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
GB2421909A (en) 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
US7628027B2 (en) 2005-07-19 2009-12-08 Hussmann Corporation Refrigeration system with mechanical subcooling
ITMI20051560A1 (en) 2005-08-10 2007-02-11 Tiberio Bruzzese COMPOSITION OF N-3 FATTY ACIDS WITH HIGH CONCENTRATION OF EPA AND E-O DHA AND CONTAINING N-6 FATTY ACIDS
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
CA2634139C (en) * 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
EP2526937A1 (en) * 2006-02-07 2012-11-28 Mochida Pharmaceutical Co., Ltd. Composition for prevention of recurrence of stroke
US20090304784A1 (en) * 2006-07-28 2009-12-10 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
PT2395991E (en) * 2009-02-10 2013-09-03 Amarin Pharmaceuticals Ie Ltd Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
KR101958515B1 (en) * 2009-06-15 2019-03-14 아마린 파마, 인크. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
CA2916208A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Similar Documents

Publication Publication Date Title
RU2001121185A (en) High purity ethyl EPA and other derivatives of EPA for psychiatric and neurological disorders
EE04629B1 (en) Use of Highly Purified Ethyl-EPA and Other EPA Derivatives for the Preparation of a Drug for the Treatment of Psychiatric and Neurological Diseases
DE60217103T2 (en) REINFORCED EFFECT OF MULTIPLE UNSATURATED FATTY ACIDS
EP3159329B1 (en) Use of 2-hidroxyderivates of polyunsaturated fatty acids as medicaments
JP4634008B2 (en) 2H-benzimidazol-2-one, 1,3-dihydro-1- (2- {4- [3- (trifluoromethyl) phenyl] -1-piperazinyl} ethyl)-and its physiologically acceptable acids New use of addition salts
HUP0100155A2 (en) Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
US20050147665A1 (en) Pharmaceutical and nutritional compositions
RU2002133098A (en) THERAPEUTIC COMBINATIONS OF FATTY ACIDS
JP2001510799A (en) Therapeutic and dietary compositions comprising essential fatty acids and bioactive disulfides
JP2014517050A5 (en)
JP7025212B2 (en) Compounds, compositions and methods for the treatment of inflammatory, degenerative and neurodegenerative diseases
JP2001503743A (en) Therapeutic agent containing eicosapentaenoic acid and / or stearidonic acid
HRP20200394T1 (en) Mixture of fatty acids (f.a.g., fatty acids group) for use in the treatment of inflammatory pathologies
JP2008540484A5 (en)
JP2007518764A5 (en)
JP2007518764A (en) Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disorders
FI101377B1 (en) Process for the preparation of N-alkylated 1,4-dihydropyridine compounds
JPH0672868A (en) Antipsychotic agent
JP2002540146A5 (en)
JP3731983B2 (en) Drugs for improving night noise in dementia dogs
US20170296499A1 (en) Combinational compositions and methods of use thereof
CA3020087A1 (en) Combinational compositions and methods of use thereof
WO2000044360A2 (en) Drugs for treatment of psychiatric and brain disorders
JPH01272576A (en) Hydroquinonylphenylbutyric acid amide derivative
TH76781A (en) Treatment of anorexia (AN) and persistent hunger